Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population

Clinical Therapeutics

Volumn 35, Issue 8, 2013, Pages 1201-1210

  Deitelzweig, Steven B ^a   Buysman, Erin ^b   Pinsky, Brett ^b   Lacey, Michael ^b   Jing, Yonghua ^c   Wiederkehr, Daniel ^d   Graham, John ^c  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b OPTUM   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

Author keywords

Anticoagulant; Claims analysis; Managed care; Risk assessment; Stroke

Indexed keywords

WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DEMOGRAPHY; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE PLANNING; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; NONVALVULAR ATRIAL FIBRILLATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

ANTICOAGULANT; CLAIMS ANALYSIS; MANAGED CARE; RISK ASSESSMENT; STROKE;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HOSPITALIZATION; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MANAGED CARE PROGRAMS; MEDICATION ADHERENCE; MIDDLE AGED; RISK FACTORS; STROKE; TIME FACTORS; WARFARIN; YOUNG ADULT;

EID: 84882901632     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.06.005     Document Type: Article

References (30)

1. Fuster V., Ryden L.E., Cannom D.S., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011, 123:e269-e367.
2. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
3. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114:119-125.
4. Naccarelli G.V., Varker H., Lin J., Schulman K.L. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009, 104:1534-1539.
5. Fitch K, Iwasaki K, Pyenson B. Non-valvular atrial fibrillation & anticoagulation therapy: an actuarial study of the Medicare population. 2010. Accessed July 9, 2012. http://publications.milliman.com/research/health-rr/pdfs/non-valvular-atrial-fibrillation.pdf.
6. You J.J., Singer D.E., Howard P.A., et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e531S-e5575.
7. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
8. Petersen P. Thromboembolic complications in atrial fibrillation. Stroke 1990, 21:4-13.
9. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005:CD001927.
10. Miller C.S., Grandi S.M., Shimony A., et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012, 110:453-460.
11. Piccini J.P., Mi X., Dewald T.A., et al. Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm 2012, 9:1403-1408.
12. Kowey P.R., Reiffel J.A., Myerburg R., et al. Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry). Am J Cardiol 2010, 105:1130-1134.
13. Gross C.P., Vogel E.W., Dhond A.J., et al. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther 2003, 25:1750-1764.
14. Kutner M., Nixon G., Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991, 151:1950-1953.
15. Ogilvie I.M., Newton N., Welner S.A., et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010, 123:638-645.
16. Goodman L., Brunton L., Chabner B., Knollman B. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2011, McGraw-Hill, New York, NY. 12 ed.
17. Nutescu E., Chuatrisorn I., Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011, 31:326-343.
18. Harder S., Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996, 30:416-444.
19. Holbrook A.M., Pereira J.A., Labiris R., et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005, 165:1095-1106.
20. Holbrook A., Schulman S., Witt D.M., et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141. e152S-1184S.
21. Song X., Sander S.D., Varker H., Amin A. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs 2012, 12:245-253.
22. Fang M.C., Go A.S., Chang Y., et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010, 3:624-631.
23. Health insurance portability and accountability act of 1996. Public law 104-191, 104th Congress. 1996. Accessed February 13, 2013. http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf.
24. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
25. Pisters R., Lane D.A., Nieuwlaat R., et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138:1093-1100.
26. Go A.S., Hylek E.M., Phillips K.A., et al. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation 2000, 102:11-13.
27. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation.
28. Camm A.J., Kirchhof P., Lip G.Y., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31:2369-2429.
29. Brown T.M., Siu K., Walker D., et al. Development of a conceptual model of adherence to oral anticoagulants to reduce risk of stroke in patients with atrial fibrillation. J Manag Care Pharm 2012, 18:351-362.
30. HCUP Comorbidity Software. Healthcare Cost and Utilization Project (HCUP). 2013. Accessed February 6, 2013. http://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp.